Generation of Potent and Stable Human CD4+ T Regulatory Cells by Activation-independent Expression of FOXP3
Overview
Pharmacology
Authors
Affiliations
Therapies based on enhancing the numbers and/or function of T regulatory cells (Tregs) represent one of the most promising approaches to restoring tolerance in many immune-mediated diseases. Several groups have investigated whether human Tregs suitable for cellular therapy can be obtained by in vitro expansion, in vitro conversion of conventional T cells into Tregs, or gene transfer of the FOXP3 transcription factor. To date, however, none of these approaches has resulted in a homogeneous and stable population of cells that is as potently suppressive as ex vivo Tregs. We developed a lentivirus-based strategy to ectopically express high levels of FOXP3 that do not fluctuate with the state of T-cell activation. This method consistently results in the development of suppressive cells that are as potent as Tregs and can be propagated as a homogeneous population. Moreover, using this system, both naïve and memory CD4(+) T cells can be efficiently converted into Tregs. To date, this is the most efficient and reliable protocol for generating large numbers of suppressive CD4(+) Tregs, which can be used for further biological study and developed for antigen-specific cellular therapy applications.
Harnessing the biology of regulatory T cells to treat disease.
Wardell C, Boardman D, Levings M Nat Rev Drug Discov. 2024; 24(2):93-111.
PMID: 39681737 DOI: 10.1038/s41573-024-01089-x.
Doglio M, Ugolini A, Bercher-Brayer C, Camisa B, Toma C, Norata R Nat Commun. 2024; 15(1):2542.
PMID: 38538608 PMC: 10973480. DOI: 10.1038/s41467-024-46448-9.
Treg in inborn errors of immunity: gaps, knowns and future perspectives.
Kennedy-Batalla R, Acevedo D, Luo Y, Esteve-Sole A, Vlagea A, Correa-Rocha R Front Immunol. 2024; 14:1278759.
PMID: 38259469 PMC: 10800401. DOI: 10.3389/fimmu.2023.1278759.
Tuomela K, Levings M Diabetologia. 2024; 67(4):611-622.
PMID: 38236408 DOI: 10.1007/s00125-023-06076-2.
Sato Y, Nathan A, Shipp S, Wright J, Tate K, Wani P Mol Ther Methods Clin Dev. 2023; 31:101150.
PMID: 38027059 PMC: 10679769. DOI: 10.1016/j.omtm.2023.101150.